On Tuesday, March 12, Amphastar Pharmaceutical AMPH will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release.
Earnings and Revenue
Wall Street expects EPS of 11 cents and sales around $78.18 million.
If the company were to post earnings inline with the consensus estimate when it reports Tuesday, EPS would be up 10 percent. Revenue would be up 29.43 percent from the year-ago period. Here's how the company's reported EPS has compared to analyst estimates in the past:
Quarter | Q3 2018 | Q2 2018 | Q1 2018 | Q4 2017 |
EPS Estimate | 0.11 | 0.07 | 0.08 | -0.02 |
EPS Actual | 0.12 | 0.03 | -0.05 | 0.1 |
Stock Performance
For a full 12 months, the return has risen by 23.93 percent. Given that these returns are generally positive, long-term shareholders are probably relaxed going into this earnings release. Long-term shareholders are already enjoying 12-month gains prior to the announcement.
Analysts have adjusted their estimates higher for EPS and revenues over the past 90 days. The average rating by analysts on Amphastar Pharmaceutical stock is a Neutral. The strength of this rating has maintained conviction over the past 90 days.
Conference Call
Amphastar Pharmaceutical is scheduled to hold a conference call at 5:00 p.m. ET and it can be accessed here: https://edge.media-server.com/m6/p/zijvf4hd
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.